These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 28295188

  • 1. How we manage iron overload in sickle cell patients.
    Coates TD, Wood JC.
    Br J Haematol; 2017 Jun; 177(5):703-716. PubMed ID: 28295188
    [Abstract] [Full Text] [Related]

  • 2. Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation.
    Stanley HM, Friedman DF, Webb J, Kwiatkowski JL.
    Pediatr Blood Cancer; 2016 Aug; 63(8):1414-8. PubMed ID: 27100139
    [Abstract] [Full Text] [Related]

  • 3. The use of MRI to monitor iron overload in SCD.
    Wood JC.
    Blood Cells Mol Dis; 2017 Sep; 67():120-125. PubMed ID: 28927633
    [No Abstract] [Full Text] [Related]

  • 4. Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload.
    Hankins JS, Smeltzer MP, McCarville MB, Aygun B, Hillenbrand CM, Ware RE, Onciu M.
    Eur J Haematol; 2010 Jul; 85(1):51-7. PubMed ID: 20374273
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.
    Badawy SM, Liem RI, Rigsby CK, Labotka RJ, DeFreitas RA, Thompson AA.
    Br J Haematol; 2016 Nov; 175(4):705-713. PubMed ID: 27507431
    [Abstract] [Full Text] [Related]

  • 7. Myocardial Iron Overload in Sickle Cell Disease: A Rare But Potentially Fatal Complication of Transfusion.
    Tavares AHJ, Benites BD, Fertrin KY.
    Transfus Med Rev; 2019 Jul; 33(3):170-175. PubMed ID: 31153715
    [Abstract] [Full Text] [Related]

  • 8. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M, Borgna-Pignatti C.
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [Abstract] [Full Text] [Related]

  • 9. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA.
    Drugs; 2011 Jan 22; 71(2):155-77. PubMed ID: 21275444
    [Abstract] [Full Text] [Related]

  • 10. The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.
    Soulières D, Mercier-Ross J, Fradette C, Rozova A, Tsang YC, Tricta F.
    Ann Hematol; 2022 Mar 22; 101(3):533-539. PubMed ID: 34981144
    [Abstract] [Full Text] [Related]

  • 11. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.
    Eur J Haematol; 2010 Jan 01; 84(1):72-8. PubMed ID: 19732137
    [Abstract] [Full Text] [Related]

  • 12. Post-transfusional iron overload in the haemoglobinopathies.
    Thuret I.
    C R Biol; 2013 Mar 01; 336(3):164-72. PubMed ID: 23643400
    [Abstract] [Full Text] [Related]

  • 13. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
    Tsouana E, Kaya B, Gadong N, Hemmaway C, Newell H, Simmons A, Whitmarsh S, Telfer P.
    Eur J Haematol; 2015 Apr 01; 94(4):336-42. PubMed ID: 25138173
    [Abstract] [Full Text] [Related]

  • 14. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease.
    Brittenham GM, Sheth S, Allen CJ, Farrell DE.
    Semin Hematol; 2001 Jan 01; 38(1 Suppl 1):37-56. PubMed ID: 11206960
    [Abstract] [Full Text] [Related]

  • 15. Transfusion Therapy in Children With Sickle Cell Disease.
    Inati A, Mansour AG, Sabbouh T, Amhez G, Hachem A, Abbas HA.
    J Pediatr Hematol Oncol; 2017 Mar 01; 39(2):126-132. PubMed ID: 27509379
    [Abstract] [Full Text] [Related]

  • 16. Korean guideline for iron chelation therapy in transfusion-induced iron overload.
    Jang JH, Lee JH, Yoon SS, Jo DY, Kim HJ, Chung J, Lee JW, Korean Society of Hematology Aplastic Anemia Working Party.
    J Korean Med Sci; 2013 Nov 01; 28(11):1563-72. PubMed ID: 24265517
    [Abstract] [Full Text] [Related]

  • 17. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias.
    Ho PJ, Tay L, Lindeman R, Catley L, Bowden DK.
    Intern Med J; 2011 Jul 01; 41(7):516-24. PubMed ID: 21615659
    [Abstract] [Full Text] [Related]

  • 18. Iron overload in adults with sickle cell disease who have received intermittent red blood cell transfusions.
    Pack-Mabien A, Brown B, Herbert DE, Haynes J.
    J Am Assoc Nurse Pract; 2015 Oct 01; 27(10):591-6. PubMed ID: 25711464
    [Abstract] [Full Text] [Related]

  • 19. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
    Kwiatkowski JL, Cohen AR, Garro J, Alvarez O, Nagasubramanian R, Sarnaik S, Thompson A, Woods GM, Schultz W, Mortier N, Lane P, Mueller B, Yovetich N, Ware RE, SWiTCH Study Investigators.
    Am J Hematol; 2012 Feb 01; 87(2):221-3. PubMed ID: 22120913
    [Abstract] [Full Text] [Related]

  • 20. Chelation therapy for iron overload.
    Barton JC.
    Curr Gastroenterol Rep; 2007 Mar 01; 9(1):74-82. PubMed ID: 17335681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.